Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenotyping CYP3A4 Activity in Prostate Cancer vs Other Solid Tumors
NCT05518799Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Open-label trial of midazolam (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Cytochrome P450 3A4 activity at 1 day. Started Apr 2021; status: completed.
02
Drugs
midazolam
Beyond the preview
Go deeper on NCT05518799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518799.